TRGNF News and Press, Transgene S.A. From 01/19/21

Transgene (TRGNF) has received approval in France to proceed with a Phase I/IIa study of the novel oncolytic Vaccinia virus BT-001 developed with Invir.IO platform.This announcement follows approval received in December 2020 in Belgium. The first patient is expected to be enrolled in this tri...

Transgene (TRGNF): Q3 Operating revenue of €2M (-44% Y/Y)Cash and cash equivalents of €45.3M as of September 30, 2020.On October 20, 2020, company made an early repayment of the €10M loan granted by the European Investment Bank.Press Release For further details see...

Transgene ([[TRGNF]]), NEC Corp ([[NIPNF]]) and BostonGene have announced a strategic collaboration for two Phase 1 trials of TG4050, an individualized therapeutic vaccine for ovarian and head & neck cancers.TG4050 is based on Transgene’s proprietary myvac platform and NEC...

Transgene ( OTCPK:TRGNF )  raised $22.2M from the sale of 10.3M shares of its minority stake in Tasly BioPharmaceuticals to a Chinese investment fund, representing 38% of its total holding in Tasly BioPharmaceuticals. More news on: Transgene SA, Healthcare stocks news, , Read mor...

Ultra-thinly traded micro cap Transgene ( OTCPK:TRGNF +9.0% ) is up, albeit on turnover of only 2,100 shares, on the heels of a  pooled analysis of data from a Phase 1b/2 clinical trial evaluating its HPV16-targeted therapeutic vaccine TG4001, combined with Pfizer ( PFE +3.7% ) a...

Transgene S.A.  ( OTCPK:TRGNF ): Q1 Revenue of €3M (+50.0% Y/Y). More news on: Transgene SA, Earnings news and commentary, Tech stocks news, , Read more ...

Noteworthy events during the week of November 4 - 10 for healthcare investors. More news on: Dare Bioscience, Inc., EyePoint Pharmaceuticals, Inc., Aduro Biotech, Healthcare stocks news, , Read more ...

Transgene S.A.  ( OTCPK:TRGNF ): Q3 Revenue of €37.5M (+2243.8% Y/Y) More news on: TRANSGENE S.A., Earnings news and commentary, Tech stocks news, , Read more ...

French biotech Transgene ( OTCPK:TRGNF ) updates investors on its key clinical studies. More news on: TRANSGENE S.A., Healthcare stocks news, Read more ...

Transgene S.A. ( OTCPK:TRGNF ): 1H GAAP EPS of -€0.24. More news on: TRANSGENE S.A., Earnings news and commentary, Tech stocks news, , Read more ...